🔴 Femasys is trading 6.16% down today — no clear catalyst identified

Femasys is trading at $2.74, down -6.16%, with no clear company-specific catalyst identified.

• The latest major catalyst was the August 19 FDA modular PMA pathway approval for FemBloc, which preceded the current move and was associated with earlier gains.
• Broader markets are rising, but Femasys is not clearly following today’s positive risk sentiment.
• Trading volume and activity details were unavailable; confidence remains low.